Lund, Sweden, 2013-10-03 08:30 CEST (GLOBE NEWSWIRE) --
EXINI Diagnostics enters new pharmaceutical company collaboration, aiming to clinically evaluate prostate cancer treatment. The agreement proves the commercial potential when working with pharmaceutical companies in the development and evaluation of drugs. As for BSI, this is yet another proof of its value.
The new agreement aims to use the software EXINI boneBSI to monitor disease progression in advanced prostate cancer drug treatment, using the BSI (Bone Scan Index) value as a new imaging biomarker. The cooperation is primarily designed to retrospectively evaluate the results of a phase-III trial by following the unique BSI value. The objective is to create additional insight on BSI impact, as an exploratory endpoint of the specific drug.
- "This collaboration shows that EXINI boneBSI and its BSI value can provide new and important information in evaluating cancer drugs. It is a commercial opportunity for us to work together with pharmaceutical companies in the development and evaluation of drugs", comments Magnus Aurell, CEO EXINI Diagnostics AB.
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
